Skye Bioscience Inc
NASDAQ:SKYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
VINX Corp
TSE:3784
|
JP |
Skye Bioscience Inc
Total Liabilities
Skye Bioscience Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Skye Bioscience Inc
NASDAQ:SKYE
|
Total Liabilities
$8.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
30%
|
CAGR 10-Years
11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$81.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
Skye Bioscience Inc
Glance View
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
See Also
What is Skye Bioscience Inc's Total Liabilities?
Total Liabilities
8.3m
USD
Based on the financial report for Dec 31, 2025, Skye Bioscience Inc's Total Liabilities amounts to 8.3m USD.
What is Skye Bioscience Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
11%
Over the last year, the Total Liabilities growth was 80%. The average annual Total Liabilities growth rates for Skye Bioscience Inc have been -12% over the past three years , 30% over the past five years , and 11% over the past ten years .
